The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

Ernexa Therapeutics’ “Trojan Horse” stem cells can infiltrate ovarian tumors in mice, boosting T cell activity and leading to shrunken tumors and improved survival, the company announced in a June 2 ...

Ovarian cancer remains one of the most difficult-to-treat diseases. With all our advances in screening and molecular profiling, it still maintains the worst death-to-diagnosis rate among gynecologic ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer. Research has shed light on how a new type of antibody treatment reactivates ...

Cancer that develops in the ovaries (the egg-producing reproductive organs) is referred to as ovarian cancer. There are three types of ovarian cancer. Each type has differences in how they will ...

Geordan Pursglove, LIXTE’s Chief Executive Officer, added: “Expansion of this important trial is in keeping with LIXTE’s mission of treating cancer with exceptional, innovative therapies and ...

“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment. Doctors may be ...

A recent study published in Engineering has shed light on the potential therapeutic effects of dihydrotanshinone I (DHT), a ...